MedTech Market Access Trends in 2022: Embracing Change and Dealing with It
More from Drug Pricing
The Swiss giant has been talking to the US government about selling medicines directly to patients.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
More from Scrip
Discover the latest trends in RNA-based therapeutics and learn how sponsors can successfully navigate the road to next generation innovation. Listen in as Citeline chats with the Director of Therapeutics at Novotech, a CRO experienced in RNA development.
Learn more about the challenges faced by today’s drug developers and the critical factors to consider as sponsors navigate the supply chain, keep up with regulatory requirements, and ensure patient access. Discover more about the role of generics and how Aspire Pharma can help.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.